Tinzaparin
Tinzaparin is a low-molecular-weight heparin (LMWH) with anticoagulant properties. It works by enhancing the inhibition of activated factor X (Factor Xa) by antithrombin III, thereby preventing thrombin formation and blood clot propagation.
Dosage by Body Weight
Administered subcutaneously. The standard therapeutic dosage for acute DVT/PE is 175 anti-Xa IU per kg of body weight once daily. Dosage must be adjusted based on actual body weight and renal function. Do not administer intramuscularly.
- Body Weight
- Below 5 kg
- Dose
- Not routine / Specialist directed
- Frequency
- Use only if prescribed
- Tracking Notes
- Safety and efficacy in pediatric patients are not fully established. Use requires strict specialist supervision and anti-Xa level monitoring.
- Body Weight
- 5-7 kg
- Dose
- 875 - 1225 IU subcutaneously
- Frequency
- Once daily
- Tracking Notes
- Calculated at therapeutic dose of 175 IU/kg. Requires careful monitoring of anti-Xa levels, especially in infants.
- Body Weight
- 8-10 kg
- Dose
- 1400 - 1750 IU subcutaneously
- Frequency
- Once daily
- Tracking Notes
- Calculated at therapeutic dose of 175 IU/kg. Dose adjustment may be needed based on clinical response and renal function.
- Body Weight
- 11-15 kg
- Dose
- 1925 - 2625 IU subcutaneously
- Frequency
- Once daily
- Tracking Notes
- Calculated at therapeutic dose of 175 IU/kg. Administer using appropriate syringe size for accurate dosing.
- Body Weight
- 16-20 kg
- Dose
- 2800 - 3500 IU subcutaneously
- Frequency
- Once daily
- Tracking Notes
- Calculated at therapeutic dose of 175 IU/kg. Regular monitoring of platelet count is recommended during therapy.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine / Specialist directed | Use only if prescribed | Safety and efficacy in pediatric patients are not fully established. Use requires strict specialist supervision and anti-Xa level monitoring. |
| 5-7 kg | 875 - 1225 IU subcutaneously | Once daily | Calculated at therapeutic dose of 175 IU/kg. Requires careful monitoring of anti-Xa levels, especially in infants. |
| 8-10 kg | 1400 - 1750 IU subcutaneously | Once daily | Calculated at therapeutic dose of 175 IU/kg. Dose adjustment may be needed based on clinical response and renal function. |
| 11-15 kg | 1925 - 2625 IU subcutaneously | Once daily | Calculated at therapeutic dose of 175 IU/kg. Administer using appropriate syringe size for accurate dosing. |
| 16-20 kg | 2800 - 3500 IU subcutaneously | Once daily | Calculated at therapeutic dose of 175 IU/kg. Regular monitoring of platelet count is recommended during therapy. |
Formulation
Purpose
Used for the treatment of acute deep vein thrombosis (DVT) with or without pulmonary embolism (PE), and for the prevention of clotting in extracorporeal circuits during hemodialysis.
Generic Name
Tinzaparin sodiumBranded Drug Names
Tinzaparin is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.